Form 4: Procept BioRobotics CEO Reza Zadno Sells Shares Under 10b5-1 Trading Plan
SEC Form 4
Procept BioRobotics CEO Reza Zadno sold a total of 26,420 shares of common stock on November 20, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Reza Zadno, CEO of Procept BioRobotics, executed multiple sales of the company's common stock on November 20, 2024.
- These sales were conducted under a pre-established Rule 10b5-1 trading plan adopted on August 8, 2024.
- A total of 26,420 shares were sold in three separate transactions at weighted average prices.
- The first transaction involved 10,111 shares sold at an average price of $92.1206 per share.
- The second transaction involved 15,809 shares sold at an average price of $92.8174 per share.
- The third transaction involved 500 shares sold at an average price of $93.884 per share.
- Following these transactions, Mr. Zadno still beneficially owns 205,605 shares of Procept BioRobotics common stock.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock sales by an executive under a pre-arranged plan. It is neither positive nor negative in itself.
Risks
- Executive stock sales can sometimes be perceived negatively by the market, potentially impacting the stock price.
Industry Context
Executive stock sales are a common occurrence, and the use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading. This filing is a routine disclosure of such activity.
Comparison to Industry Standards
- The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the medical device sector like Procept BioRobotics.
- Companies such as Intuitive Surgical (ISRG) and Stryker (SYK) also have executives who utilize similar trading plans for stock transactions.
- The reported sales are within the typical range of executive stock transactions and do not appear to be unusual compared to industry norms.
Stakeholder Impact
- The stock sales may have a minor impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 08/08/2024 | Date the Rule 10b5-1 trading plan was adopted by Reza Zadno. |
| 11/20/2024 | Date of the stock sales by Reza Zadno. |
| 11/22/2024 | Date the Form 4 was signed. |
Keywords
insider trading, stock sale, Rule 10b5-1, Reza Zadno, Procept BioRobotics, PRCT, executive stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.